Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Ambiopharm
AddedFeb 15, 2024
UpdatedJun 18, 2026
Ambiopharm

Ambiopharm

Private Equity

AmbioPharm: Rapid, cost-effective manufacturing of pharmaceutical ingredients and complex peptides.

HQ
Beech Island, SC, US
Founded
2005
Overview
Compare
Fundraising
Employees
Website

Founded with a mission to provide rapid, cost-effective manufacturing of pharmaceutical ingredients and complex peptides, AmbioPharm specializes in the development and production of active pharmaceutical ingredients (APIs) and generic peptides. The company supports pharmaceutical and biotech companies by offering services that range from preclinical and clinical development to commercial manufacturing. Their product offerings include GMP and non-GMP services, custom peptide synthesis, vaccine services, and cosmetic peptide manufacturing.

AmbioPharm has garnered attention for its responsive business model and rapid manufacturing processes. Notable affiliated individuals include members of their experienced management team, who bring extensive expertise in pharmaceutical manufacturing. Key achievements include a robust FDA inspection history and successful partnerships with leading biotech firms. The company's impact is evident in its ability to accelerate the development timelines for peptide projects, thereby contributing significantly to advancements in medical research and treatment.

Ambiopharm - Similar Companies

AmideBio logo

AmideBio

amidebio.com

Apertus Pharmaceuticals logo

Apertus Pharmaceuticals

Mytide Therapeutics logo

Mytide Therapeutics

Amerigen Pharmaceuticals logo

Amerigen Pharmaceuticals

amerigenpharma.com

Bright Path Laboratories logo

Bright Path Laboratories

brightpathlabs.com

Phlow logo

Phlow

phlow-usa.com

August Bioservices logo

August Bioservices

augustbio.com

Amphastar Pharmaceuticals logo

Amphastar Pharmaceuticals

amphastar.com

BiotechInnova logo

BiotechInnova

biotechinnova.com

Pharmaceutics International logo

Pharmaceutics International

Pharmapotheca A logo

Pharmapotheca A

chemapotheca.com

Bionpharma logo

Bionpharma

bionpharma.com

AmericanPharma Technologies logo

AmericanPharma Technologies

Catalent logo

Catalent

catalent.com

PleoPharma logo

PleoPharma

pleopharma.com

Ambiopharm - Quick Facts

Who are Ambiopharm's competitors?

Companies similar to Ambiopharm include AmideBio, Apertus Pharmaceuticals, Mytide Therapeutics and Amerigen Pharmaceuticals.

When was Ambiopharm founded?

Ambiopharm was founded in 2005.

Where is Ambiopharm's headquarters located?

Ambiopharm's headquarters is located in Beech Island, SC, US.

How much has Ambiopharm raised to-date?

As of Sep 10, 2018, Ambiopharm has raised a total of $24M (USD).

How many employees does Ambiopharm have?

Ambiopharm has 79 employees as of Feb 4, 2024.

Ambiopharm - Classification

Geographic Exposure
  • Global
Model
  • Manufacturing
Customer
  • Enterprise
Main Product
  • Peptides
  • Pharmaceuticals
Tags
  • API
  • Biotech
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 2830Drugs
  • 2834Pharmaceutical Preparations